ArticleAnnals of the American Thoracic Society2023
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.
Open access · greenAbstract read
In one paragraph
Article in Annals of the American Thoracic Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2025Pooled it
- Correlation Between CT-Derived Bhalla Score and Lung Ultrasound Score in Adult Patients with Cystic Fibrosis.Diagnostics (Basel, Switzerland) · 2026Article
- Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center.Pulmonary therapy · 2026Article
- Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study.Annals of the American Thoracic Society · 2026Article
- Challenges and opportunities for drug development in rare pulmonary diseases like cystic fibrosis: an industry perspective.Current opinion in pulmonary medicine · 2025Review
- Hypercubes to identify geomarkers of rapid cystic fibrosis lung disease progression.BMC medical informatics and decision making · 2025Article
- A Joint Model for (Un)Bounded Longitudinal Markers, Competing Risks, and Recurrent Events Using Patient Registry Data.Statistics in medicine · 2025Article
- Human-based complexFrontiers in cell and developmental biology · 2025Review
- Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CF.Pediatric pulmonology · 2024Article
- Robust identification of environmental exposures and community characteristics predictive of rapid lung disease progression.The Science of the total environment · 2024Article
- Impact of day-to-day variation in FEV1 on measures of change: A conceptual description.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Bayesian two-stage modeling of longitudinal and time-to-event data with an integrated fractional Brownian motion covariance structure.Biometrics · 2024Article
- Social-environmental phenotypes of rapid cystic fibrosis lung disease progression in adolescents and young adults living in the United States.Environmental advances · 2023Article
- Nasal polyposis from cystic fibrosis in children - the experience of a single center.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 16 institutions in 8 countries.
Rhonda SzczesniakDivision of Biostatistics & Epidemiology and.ORCID 0000-0003-0705-715X
Eleni-Rosalina AndrinopoulouDepartment of Biostatistics and.
Weiji SuDivision of Biostatistics & Epidemiology and.
Pedro M AfonsoDepartment of Biostatistics and.
Pierre-Régis BurgelCochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
Elizabeth CromwellCystic Fibrosis Foundation, Bethesda, Maryland.
Emrah GeciliDivision of Biostatistics & Epidemiology and.
Enas GhulamDivision of Biostatistics & Epidemiology and.
Christopher H GossDepartment of Medicine.
Nicole Mayer-HamblettDepartment of Pediatrics, and.
Ruth H KeoghDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Theodore G LiouDivision of Respiratory, Critical Care and Occupational Pulmonary Medicine, Department of Internal Medicine, School of Medicine, and.ORCID 0000-0003-0121-4847
Bruce MarshallCystic Fibrosis Foundation, Bethesda, Maryland.
Wayne J MorganDepartment of Pediatrics, University of Arizona, Tucson, Arizona.
Joshua S OstrengaCystic Fibrosis Foundation, Bethesda, Maryland.
David J Pastaformerly ICON Clinical Research, San Francisco, California.ORCID 0000-0003-0903-9828
Sanja StanojevicDepartment of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
Claire WainwrightChildren's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia.
Grace C ZhouDivision of Biostatistics & Epidemiology and.
Gabriela FernandezCystic Fibrosis Foundation, Bethesda, Maryland.
Aliza K FinkCystic Fibrosis Foundation, Bethesda, Maryland.
Michael S SchechterChildrens Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia.
Cystic Fibrosis Foundation · USCancer Research And Biostatistics · USErasmus MC · NLCincinnati Children's Hospital Medical Center · USDalhousie University · CAEli Lilly (United States) · USHôpital Cochin · FRInternational Council of Ophthalmology · USKing Saud bin Abdulaziz University for Health Sciences · SALondon School of Hygiene & Tropical Medicine · GBPediatrics and Genetics · USThe University of Queensland · AUUniversity of Arizona · USUniversity of Utah · USUniversity of Washington · USVirginia Commonwealth University · US
Funding
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7MTranslational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4MR01- Mapping environmental contributions to rapid lung disease progression in cystic fibrosisR01HL141286 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI SZCZESNIAK, RHONDA · 2019 to 2023
$2.3MExplanatory models of CF Survival, Infection and Intermediate Clinical OutcomesR01HL125520 · NHLBI · UNIVERSITY OF UTAH · PI LIOU, THEODORE GEH-LU · 2015 to 2018
$1.4MMedical Research Council MR/S017968/1NHLBI NIH HHS R01 HL125520NHLBI NIH HHS R01 HL141286NHLBI NIH HHS R01HL141286NIDDK NIH HHS P30 DK089507NIEHS NIH HHS P30 ES006694
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cystic FibrosisLung TransplantationAdultAgedForced Expiratory VolumeHumansLungRespiratory Function Testsepidemiologylongitudinal analysispulmonary functionrate of declineregistry analysis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.